Clinical Trial Update: Cabozantinib and Nivolumab for Carcinoid Tumors [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of cabozantinib and nivolumab for carcinoid tumors has completed with results posted in January 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Gastrointestinal Carcinoid Tumor
• Neuroendocrine Tumor

Drugs mentioned

• Cabometyx (cabozantinib)
• OPDIVO (nivolumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Carcinoid Tumor, Carcinoid Tumor of GI System | Phase 2 | Status: COMPLETED | Results posted: 2025-01-31